ISCHEMIC ATTACK AND MINOR STROKE Clinical Trials

9 clinical trials for ISCHEMIC ATTACK AND MINOR STROKE across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• NUANCE-ICAD: EFFECT OF GENOTYPE-GUIDED ORAL P2Y12 INHIBITOR SELECTION VS CONVENTIONAL CLOPIDOGREL THERAPY IN SYMPTOMATIC INTRACRANIAL ATHEROSCLEROTIC DISEASE: A PILOT PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLINDED-ENDPOINT (PROBE) MULTI-CENTRE STUDY — RECRUITING
• FOCAL CEREBRAL ARTERIOPATHY STEROID (FOCAS) TRIAL — RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF MILVEXIAN, AN ORAL FACTOR XIA INHIBITOR, FOR STROKE PREVENTION AFTER AN ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK — RECRUITING · PHASE3
• RANDOMIZED EFFICACY AND SAFETY TRIAL WITH ORAL S 44819 AFTER RECENT ISCHEMIC CEREBRAL EVENT INTERNATIONAL, MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PHASE II STUDY — RECRUITING · PHASE2
• A RANDOMIZED CONTROLLED TRIAL OF TNK-TPA VERSUS STANDARD OF CARE FOR MINOR ISCHEMIC STROKE WITH PROVEN OCCLUSION — RECRUITING
• PLATELET-ORIENTED INHIBITION IN NEW TIA AND MINOR ISCHEMIC STROKE (POINT) TRIAL, A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER CLINICAL TRIAL — RECRUITING
• A GLOBAL, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, RESPONSE-ADAPTIVE DOSE-RANGING STUDY OF BMS-986177, AN ORAL FACTOR XIA INHIBITOR, FOR THE PREVENTION OF NEW ISCHEMIC STROKE OR NEW COVERT BRAIN INFARCTION IN PATIENTS RECEIVING ASPIRIN AND CLOPIDOGREL FOLLOWING ACUTE ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK (TIA) — COMPLETED · PHASE2
• A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE, PHASE III STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TICAGRELOR AND ASA COMPARED WITH ASA IN THE PREVENTION OF STROKE AND DEATH IN PATIENTS WITH ACUTE ISCHAEMIC STROKE OR TRANSIENT ISCHAEMIC ATTACK [THALES - ACUTE STROKE OR TRANSIENT ISCHAEMIC ATTACK TREATED WITH TICAGRELOR AND ASA FOR PREVENTION OF STROKE AND DEATH — COMPLETED · PHASE3
• CLINICAL PROTOCOL: A PHASE 2, PLACEBO CONTROLLED, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BMS-986141 FOR THE PREVENTION OF RECURRENT BRAIN INFARCTION IN SUBJECTS RECEIVING ACETYLSALICYCLIC ACID (ASA) FOLLOWING ACUTE ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK — NOT_YET_RECRUITING · PHASE2

Refine this search